OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID ‐19
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 5, pp. 826-829
Open Access | Times Cited: 18
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 5, pp. 826-829
Open Access | Times Cited: 18
Showing 18 citing articles:
Efficacy of antiviral therapy and disease outcomes in COVID-19 patients previously treated with obinutuzumab for follicular lymphoma
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
An international multicenter study comparing COVID ‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Tali Shafat, Daniel Grupel, Tzvika Porges, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
Erica Franceschini, Mariachiara Pellegrino, Vera Todisco, et al.
Infection (2023) Vol. 51, Iss. 5, pp. 1577-1581
Open Access | Times Cited: 10
Erica Franceschini, Mariachiara Pellegrino, Vera Todisco, et al.
Infection (2023) Vol. 51, Iss. 5, pp. 1577-1581
Open Access | Times Cited: 10
Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab—Challenging Recognition and Treatment
Ewa Łyżwa, Małgorzata Sobiecka, Katarzyna Lewandowska, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 693-693
Open Access | Times Cited: 9
Ewa Łyżwa, Małgorzata Sobiecka, Katarzyna Lewandowska, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 693-693
Open Access | Times Cited: 9
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Igor Aurer, Ozren Jakšić, Sandra Bašić‐Kinda, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 331-331
Open Access | Times Cited: 2
Igor Aurer, Ozren Jakšić, Sandra Bašić‐Kinda, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 331-331
Open Access | Times Cited: 2
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin’s Lymphoma: A Single-Center Cohort Study
Makoto Saito, Akio Mori, Takashi Ishio, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 328-328
Open Access | Times Cited: 2
Makoto Saito, Akio Mori, Takashi Ishio, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 328-328
Open Access | Times Cited: 2
Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA .5 subvariant surge
Yotam Bronstein, Shai Levi, Yair Herishanu
British Journal of Haematology (2023) Vol. 201, Iss. 6, pp. 1125-1128
Closed Access | Times Cited: 6
Yotam Bronstein, Shai Levi, Yair Herishanu
British Journal of Haematology (2023) Vol. 201, Iss. 6, pp. 1125-1128
Closed Access | Times Cited: 6
Exposure to obinutuzumab does not affect outcomes of SARS ‐CoV ‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma
Antonio Pinto, M. Caltagirone, Marco Johannes Battista, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Antonio Pinto, M. Caltagirone, Marco Johannes Battista, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study
Wenxiu Shu, Qianqian Yang, Jing Le, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Wenxiu Shu, Qianqian Yang, Jing Le, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
A case of prolonged COVID ‐19 treated with tixagevimab/cilgavimab
Takahiro Shimizu, Hiroki Shirasaki, Kazuhiro Okafuji, et al.
Respirology Case Reports (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 4
Takahiro Shimizu, Hiroki Shirasaki, Kazuhiro Okafuji, et al.
Respirology Case Reports (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 4
ProlongedSARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy
Amalia Papanikolopoulou, VASILIS THIMIS, EIRINI ANTONOGIANNAKI, et al.
In Vivo (2023) Vol. 37, Iss. 1, pp. 461-467
Open Access | Times Cited: 2
Amalia Papanikolopoulou, VASILIS THIMIS, EIRINI ANTONOGIANNAKI, et al.
In Vivo (2023) Vol. 37, Iss. 1, pp. 461-467
Open Access | Times Cited: 2
In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?
Joleen Choy, Katharine L. Lewis
British Journal of Haematology (2024)
Open Access
Joleen Choy, Katharine L. Lewis
British Journal of Haematology (2024)
Open Access
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during COVID-19 pandemic
Mingyue Xu, Ruiying Chen, Yifeng Wang, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 11
Open Access
Mingyue Xu, Ruiying Chen, Yifeng Wang, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 11
Open Access
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
Hovav Azuly, Tali Shafat, Daniel Grupel, et al.
Infectious Diseases and Therapy (2024)
Open Access
Hovav Azuly, Tali Shafat, Daniel Grupel, et al.
Infectious Diseases and Therapy (2024)
Open Access
Prolonged SARS‐CoV ‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
Ryosuke Kambe, Masamichi Sato, Daisuke Uehara, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Ryosuke Kambe, Masamichi Sato, Daisuke Uehara, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 1
OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: SINGLE CENTER EXPERIENCE
Сања Трајкова, Svetlana Krstevska Balkanov, Aleksandra Pivkova-Veljanovska, et al.
Academic Medical Journal (2023) Vol. 3, Iss. 1, pp. 15-26
Open Access
Сања Трајкова, Svetlana Krstevska Balkanov, Aleksandra Pivkova-Veljanovska, et al.
Academic Medical Journal (2023) Vol. 3, Iss. 1, pp. 15-26
Open Access
Caution to psychiatry ward: COVID‐19 pneumonia can manifest weeks or months after testing positive with a PCR test in individuals on preexisting immune‐suppressing medication
Masaki Nakano, Michitaka Funayama, Riko Wakisaka, et al.
Psychiatry and Clinical Neurosciences Reports (2023) Vol. 2, Iss. 3
Open Access
Masaki Nakano, Michitaka Funayama, Riko Wakisaka, et al.
Psychiatry and Clinical Neurosciences Reports (2023) Vol. 2, Iss. 3
Open Access
